Key Highlights

  • Eli Lilly (NYSE:LLY) jumped 6.7% to USD 1,374.21 on October 29, 2026 after raising 2026 Revenue guidance to USD 91 billion to 92 billion. Third-quarter revenue was USD 24.4 billion against USD 22.6 billion expected, and adjusted Earnings were USD 7.48 per share.
  • Merck (NYSE:MRK) rose about 4% on October 29, 2026 after earnings, as defensive and value beats helped a rotation trade, according to one account. The earnings figures were not available, so only the direction is confirmed.
  • Insmed (NASDAQ:INSM) rose 16% on October 29, 2026 after beating revenue expectations and raising full-year guidance, according to one account. No revenue, earnings or guidance figures were available, so the size of the raise is unknown.
  • Stryker (NYSE:SYK) fell about 12% to 13% after hours on October 29, 2026 after cutting full-year guidance to adjusted earnings of USD 14.80 to 14.90 per share, against USD 14.95 consensus, and organic growth of 6.5% to 7%, against 8.2% expected.

Eli Lilly (NYSE:LLY): Large beat, raised revenue guide

Eli Lilly (NYSE:LLY) reported third-quarter results on October 29, 2026. Revenue of USD 24.4 billion beat the USD 22.6 billion consensus by about USD 1.8 billion, which is simple arithmetic on two published numbers and a gap of roughly 8%, and adjusted earnings of USD 7.48 per share beat an estimate of about USD 6.3. Management raised 2026 revenue guidance to USD 91 billion to 92 billion. The shares closed up 6.7% at USD 1,374.21. Intraday gains of 4.4% to 6.7% appeared in different accounts depending on the timestamp, but the closing figure is 6.7%, and three published accounts confirm the results and the guidance. The company release remains the primary check on every figure, and the Earnings Per Share guidance was lowered in the same release. The earnings outlook moved the other way. Adjusted earnings guidance was trimmed to USD 35 to 36 per share because acquired Research and Development charges of USD 4.57 per share are being counted. The charge is a one-time cost of buying future products, so the trimmed guide does not mean the current Business is earning less. Foundayo, the new obesity pill, reportedly fell short of expectations, and that claim comes from published accounts, so the size of the shortfall is not stated.

Merck (NYSE:MRK): Defensive earnings, direction only

Merck (NYSE:MRK) rose about 4% on October 29, 2026 after earnings. eBay (NASDAQ:EBAY) rose 3%. Shell (NYSE:SHEL) rose 2.4%. UPS (NYSE:UPS) rose 2%. Defensive and value earnings beats helped fuel a rotation trade while technology sold off. The direction of each move was verified in one account per company, but the underlying earnings figures were not in the published accounts. A pharmaceutical group, an online marketplace, an energy major and a logistics company are not natural peers, so the common link is the market backdrop and the tone of results, not the business. Earnings reactions in this group were modest compared with the double-digit moves seen elsewhere in the market, which fits the defensive character of the businesses. Readers should confirm the earnings numbers themselves in the company releases. UPS reportedly raised its 2026 revenue guidance to USD 92.6 billion from USD 91.2 billion. Simple arithmetic puts the increase at USD 1.4 billion, or about 1.5%. A raise of that size is modest, which fits a gain of about 2%, but the figure appears in a single account and should be checked against the company release. Guidance matters because it tells investors whether the current trend is expected to continue.

Insmed (NASDAQ:INSM): Raised guidance, no figures

Insmed (NASDAQ:INSM) rose 16% on October 29, 2026 after beating revenue expectations and raising guidance. On the same day Norwegian Cruise Line rose 13% after a stronger third quarter and a higher 2026 EPS guide. These are the only confirmed facts: the revenue, EPS and guidance numbers were not in the published accounts, so this article cannot say how large either beat or raise was. Each direction was confirmed in a single account, which is a thinner standard than the two-account verification used for other names. Insmed is a biopharmaceutical company, and Norwegian Cruise Line is a cruise operator, so the only link between them is the direction of their guidance. A single day of strong trading does not make either stock a trend. Guidance is management's forecast for future results, and raising it tells investors that the business is tracking ahead of plan. A raise matters more than a beat alone because it resets expectations for coming quarters, and analysts revise models accordingly. For a commercial-stage biotech such as Insmed, growth in product sales drives the revenue line, while for a cruise operator, ticket pricing and onboard spending drive results. The common thread is that both companies gave a more optimistic outlook while the technology sector sold off, which may have drawn rotation flows toward companies with improving visibility.

Stryker (NYSE:SYK): Guidance cut on both lines

Stryker (NYSE:SYK) reported after the close on October 29, 2026 and lowered its outlook for the full year. Adjusted earnings per share are now expected between USD 14.80 and USD 14.90, and the top of that range is below the USD 14.95 consensus. Organic growth, which strips out acquisitions and currency, is guided at 6.5% to 7%, against 8.2% expected by analysts. The after-hours decline of about 12% to 13% appears in two published accounts, while the premarket figure of 11.2% comes from the premarket quote. Third-quarter revenue and earnings details were not retrieved here, so only the guidance figures and share moves are stated. Guidance matters because analysts value a medical device maker on expected earnings for coming quarters. When management lowers the range, models are cut and the multiple investors will pay can shrink at the same time. Here the organic growth cut is the larger gap, since 6.5% to 7% is more than half a point below 8.2%.

Where Things Stand

The answer is that healthcare earnings split by what each company said about the future, not by sub-sector alone. Lilly raised revenue guidance, Insmed raised its full-year outlook and Merck (NYSE:MRK) rose with defensive earners, while Stryker cut both its earnings and organic growth ranges. Gaps matter: Merck (NYSE:MRK) and Insmed figures were not available, and the Lilly obesity pill Foundayo is reported to have fallen short. The next catalysts are the October 30 open, company releases and Novo Nordisk's report on November 4, 2026. This is not Investment advice.